Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05826288
Other study ID # 22-1832.cc
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 29, 2023
Est. completion date August 22, 2024

Study information

Verified date July 2023
Source University of Colorado, Denver
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess the potential for successfully using technology-assisted in-home oncology care to provide improved care coordination and management, and appropriate referral to treatment for patients receiving bone marrow transplant (BMT) or chimeric antigen receptor (CAR) T-cell therapy (CAR-T). The technology-assisted in-home oncology care program includes remote patient monitoring (RPM), telemedicine, and home-based health care services.


Description:

The objective of this study is to assess the potential for successfully using technology-assisted in-home oncology care to provide improved care coordination and management, and appropriate referral to treatment for patients receiving bone marrow transplant (BMT) or chimeric antigen receptor (CAR) T-cell therapy (CAR-T). The technology-assisted in-home oncology care program includes remote patient monitoring (RPM), telemedicine, and home-based health care services. The study focuses on evaluating the technical feasibility, operational feasibility, and perceived patient, caregiver and healthcare provider experience of a combined package of technology-assisted in-home oncology care services to monitor for febrile neutropenia, infection, cyotokine release syndrome, neurotoxicity or other symptomatic episodes needing management up to 90 days post allogeneic BMT, up to 30 days post autologous BMT, and up to 30 days post CAR-T. It includes the following specific aims and hypotheses:


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 11
Est. completion date August 22, 2024
Est. primary completion date July 12, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria: - Age 18 years to 89 years old - Bone marrow transplant recipients (allogeneic and autologous) or CAR-T patients - Determined by care provider to be stable for discharge to home setting for outpatient care according to clinical practice standard operating procedures (SOPs) - Residing in the Denver metro area for the duration of the study within 45 minutes of the AMC - Has in-home caregiver support 24/7 (i.e., does not live alone) - Has self-reported reliable telephone and home internet service and a stable wireless network - Patient agrees to not submerge the BioButton Rechargeable device in more than 3 feet of water or submerge for longer than 30 minutes at a time. - Patient owns or possesses, as the primary user with reliable daily access, a mobile device (iOS or Android) capable of running the study's mobile applications and accepting the terms and conditions - Patient has SMS texting capacity and an unlimited texting plan or other plan sufficient for study text messaging without undue patient burden - Patient is willing to complete and log a self-check of temperature twice daily and return the log to the study team at the end of the study - Patient is willing to be available for the duration of the study - Patient has access to reliable transportation to the hospital 24/7 Exclusion Criteria: - Patients will be excluded from study participation if the PI or designated care provider believes study participation would not be in the patient's best interest for clinical reasons. - Patients may also be excluded from study participation if in the opinion of the PI they have a medical condition that may impede their ability to adhere to the study protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
BioIntelliSense BioButton Rechargable
This study uses the BioIntelliSense BioButton Rechargeable for RPM, in combination with the BioSync mobile app on participants' mobile phones for data transmission, augmented by use of the BioHub as a backup transmission device. RPM monitoring of device data is accomplished through use of the AlertWatch software system.
Memora Health two-way patient engagement platform provided by RC
The Memora Health platform is designed to automate complex care workflows, making them simple for patients and clinicians to navigate. It utilizes a multi-modal communications system that primarily relies on two-way text messaging and artificial intelligence.

Locations

Country Name City State
United States University of Colorado Hospital Aurora Colorado

Sponsors (2)

Lead Sponsor Collaborator
University of Colorado, Denver Reimagine Care

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Overall patient satisfaction Number and percent of patients who report overall satisfaction with the intervention based on responses to survey items 90 days
Other Overall caregiver satisfaction Number and percent of caregivers who report overall satisfaction with the intervention based on responses to survey items up to 90 days
Other Overall health care provider satisfaction Number and percent of providers who report overall satisfaction with the intervention based on responses to survey items 90 days
Other Perceived quality of life Number and percent of patients who report overall improvement in perceived quality of life in responses to survey items 90 days
Primary Number of patients reporting symptoms Determine the number of patients reporting symptoms via EPRO 90 Days
Primary Number of alerts generated through RPM systems 30 days
Primary Number of potential febrile events detected via RPM 90 Days
Primary Number of potential infections detected via RPM 90 Days
Primary Number of potential neurotoxicity events detected via RPM 90 Days
Primary Number of potential cytokine release syndrome (CRS) events detected via RPM 90 Days
Primary Number of febrile neutropenia events confirmed by clinical evaluation 90 Days
Primary Number of infections confirmed by clinical evaluation 90 Days
Primary Number of neurotoxicity events confirmed by clinical evaluation 90 Days
Primary Number of CRS events confirmed by clinical evaluation 30 days
Primary Number of tech support contacts received from patients/caregivers 90 Days
Primary Minutes RPM devices spent off-body 90 Days
Secondary Total number of patient interactions with RC Total patient interactions with RC, by type, including EPRO text message conversations, video visits, and phone calls 90 Days
Secondary EPRO patient response rates The percentage of outbound text messages requesting a response that are responded to by persons activated on the program 90 Days
Secondary Patient retention rate The percentage of patients that remain actively engaged with the program by exchanging at least one text message or having at least one telehealth encounter with the VCC per week 90 Days
Secondary Number of calls escalated to CU/UCHealth for clinical evaluation and follow-up with study participants 90 Days
Secondary Number of hospital admissions during study period 90 Days
Secondary Length of stay for hospital admissions during study period up to 90 days
Secondary Total days in hospital during study period 90 Days
Secondary Number of emergency room visits during study period 90 Days
Secondary Number of ICU admissions during study period 90 Days
See also
  Status Clinical Trial Phase
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Recruiting NCT04092803 - Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu N/A
Active, not recruiting NCT02530463 - Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome Phase 2
Completed NCT00948064 - Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Phase 2
Completed NCT04474678 - Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!") N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Recruiting NCT03948529 - RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation Phase 2
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Active, not recruiting NCT02723994 - A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia Phase 2
Terminated NCT02469415 - Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Phase 2
Recruiting NCT04856215 - 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia Phase 2
Recruiting NCT06155188 - Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia N/A
Completed NCT00001637 - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Completed NCT02910583 - Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) Phase 2
Completed NCT01212926 - Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Recruiting NCT05866887 - Insomnia Prevention in Children With Acute Lymphoblastic Leukemia N/A